NASDAQ:DCTH Delcath Systems (DCTH) Stock Price, News & Analysis $11.12 +0.71 (+6.82%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$11.06 -0.06 (-0.55%) As of 08/22/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Delcath Systems Stock (NASDAQ:DCTH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Delcath Systems alerts:Sign Up Key Stats Today's Range$10.43▼$11.2550-Day Range$10.01▼$15.4352-Week Range$7.85▼$18.23Volume771,937 shsAverage Volume826,901 shsMarket Capitalization$388.98 millionP/E Ratio222.40Dividend YieldN/APrice Target$24.50Consensus RatingBuy Company Overview Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York. Read More Delcath Systems Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreDCTH MarketRank™: Delcath Systems scored higher than 56% of companies evaluated by MarketBeat, and ranked 475th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingDelcath Systems has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageDelcath Systems has only been the subject of 2 research reports in the past 90 days.Read more about Delcath Systems' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Delcath Systems are expected to grow in the coming year, from ($0.79) to ($0.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Delcath Systems is 222.40, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 28.44.Price to Earnings Ratio vs. SectorThe P/E ratio of Delcath Systems is 222.40, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 31.30.Price to Book Value per Share RatioDelcath Systems has a P/B Ratio of 3.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.76% of the float of Delcath Systems has been sold short.Short Interest Ratio / Days to CoverDelcath Systems has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Delcath Systems has recently increased by 29.36%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDelcath Systems does not currently pay a dividend.Dividend GrowthDelcath Systems does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.76% of the float of Delcath Systems has been sold short.Short Interest Ratio / Days to CoverDelcath Systems has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Delcath Systems has recently increased by 29.36%, indicating that investor sentiment is decreasing significantly. News and Social Media2.6 / 5News Sentiment0.74 News SentimentDelcath Systems has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Delcath Systems this week, compared to 3 articles on an average week.Search InterestOnly 7 people have searched for DCTH on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days.MarketBeat Follows4 people have added Delcath Systems to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Delcath Systems insiders have not sold or bought any company stock.Percentage Held by Insiders17.40% of the stock of Delcath Systems is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.12% of the stock of Delcath Systems is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Delcath Systems' insider trading history. Receive DCTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Delcath Systems and its competitors with MarketBeat's FREE daily newsletter. Email Address DCTH Stock News HeadlinesDelcath Systems, Inc. (NASDAQ:DCTH) Sees Significant Growth in Short InterestAugust 23 at 3:41 AM | americanbankingnews.comDelcath Systems doses first patient in Hepzato combination trialAugust 19, 2025 | msn.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history. | Paradigm Press (Ad)Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal CancerAugust 19, 2025 | finance.yahoo.comH.C. Wainwright Remains Bullish on Delcath Systems (DCTH)August 13, 2025 | msn.comDelcath Systems: Huge Potential But With The Handbrake On For NowAugust 12, 2025 | seekingalpha.comWe Like These Underlying Return On Capital Trends At Delcath Systems (NASDAQ:DCTH)August 7, 2025 | finance.yahoo.comDelcath Systems Q2 2025 Earnings PreviewAugust 6, 2025 | msn.comSee More Headlines DCTH Stock Analysis - Frequently Asked Questions How have DCTH shares performed this year? Delcath Systems' stock was trading at $12.04 on January 1st, 2025. Since then, DCTH shares have decreased by 7.6% and is now trading at $11.12. How were Delcath Systems' earnings last quarter? Delcath Systems, Inc. (NASDAQ:DCTH) issued its earnings results on Wednesday, August, 6th. The company reported $0.07 earnings per share for the quarter, beating analysts' consensus estimates of $0.02 by $0.05. The firm earned $24.16 million during the quarter, compared to analyst estimates of $22.84 million. Delcath Systems had a trailing twelve-month return on equity of 6.91% and a net margin of 3.18%. Read the conference call transcript. When did Delcath Systems' stock split? Delcath Systems shares reverse split on the morning of Tuesday, October 22nd 2019.The 1-100 reverse split was announced on Friday, October 18th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 21st 2019. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. Who are Delcath Systems' major shareholders? Delcath Systems' top institutional investors include Rosalind Advisors Inc. (9.44%), Geode Capital Management LLC (2.02%), Vivo Capital LLC (1.63%) and Marshall Wace LLP (1.38%). Insiders that own company stock include Gil Aharon, Rosalind Advisors, Inc, Gerard J Michel, Vojo Vukovic, John Purpura, Sandra Pennell and John Richard Sylvester. View institutional ownership trends. How do I buy shares of Delcath Systems? Shares of DCTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Delcath Systems own? Based on aggregate information from My MarketBeat watchlists, some other companies that Delcath Systems investors own include Predictive Oncology (POAI), Ford Motor (F), JPMorgan Chase & Co. (JPM), Zomedica (ZOM), Wells Fargo & Company (WFC), Wayfair (W) and Bank of America (BAC). Company Calendar Last Earnings8/06/2025Today8/23/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:DCTH CIK872912 Webdelcath.com Phone212-489-2100Fax212-489-2102Employees60Year FoundedN/APrice Target and Rating Average Price Target for Delcath Systems$24.50 High Price Target$31.00 Low Price Target$21.00 Potential Upside/Downside+120.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)$0.05 Trailing P/E Ratio222.40 Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.39 million Net Margins3.18% Pretax Margin4.18% Return on Equity6.91% Return on Assets5.80% Debt Debt-to-Equity RatioN/A Current Ratio10.88 Quick Ratio9.87 Sales & Book Value Annual Sales$70.24 million Price / Sales5.54 Cash FlowN/A Price / Cash FlowN/A Book Value$3.00 per share Price / Book3.71Miscellaneous Outstanding Shares34,981,000Free Float28,894,000Market Cap$388.99 million OptionableOptionable Beta0.82 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:DCTH) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersNations are at war over what’s in this boxA resource known as Element 29 is quickly becoming one of the most sought-after materials on the planet. Goldm...Behind the Markets | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredThe New Way Retirees Are Getting Paid Extra Every MonthBloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Delcath Systems, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Delcath Systems With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.